- Home
- IXHL vs EQ Comparison
IXHL vs EQ Comparison
Compare IXHL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- EQ
- Stock Information
- Founded
- IXHL 2001
- EQ 2017
- Country
- IXHL Australia
- EQ United States
- Employees
- IXHL N/A
- EQ N/A
- Industry
- IXHL
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- EQ Health Care
- Exchange
- IXHL Nasdaq
- EQ Nasdaq
- Market Cap
- IXHL 49.1M
- EQ 57.8M
- IPO Year
- IXHL N/A
- EQ 2018
- Fundamental
- Price
- IXHL $0.31
- EQ $0.97
- Analyst Decision
- IXHL
- EQ Hold
- Analyst Count
- IXHL 0
- EQ 1
- Target Price
- IXHL N/A
- EQ $1.00
- AVG Volume (30 Days)
- IXHL 17.8M
- EQ 429.4K
- Earning Date
- IXHL 11-14-2025
- EQ 11-13-2025
- Dividend Yield
- IXHL N/A
- EQ N/A
- EPS Growth
- IXHL N/A
- EQ N/A
- EPS
- IXHL N/A
- EQ N/A
- Revenue
- IXHL $12,000.00
- EQ $4,392,000.00
- Revenue This Year
- IXHL $1,188.37
- EQ N/A
- Revenue Next Year
- IXHL N/A
- EQ N/A
- P/E Ratio
- IXHL N/A
- EQ N/A
- Revenue Growth
- IXHL N/A
- EQ N/A
- 52 Week Low
- IXHL $0.08
- EQ $0.27
- 52 Week High
- IXHL $2.25
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- IXHL 38.06
- EQ 38.75
- Support Level
- IXHL $0.33
- EQ $0.95
- Resistance Level
- IXHL $0.35
- EQ $1.18
- Average True Range (ATR)
- IXHL 0.02
- EQ 0.15
- MACD
- IXHL 0.00
- EQ -0.01
- Stochastic Oscillator
- IXHL 17.77
- EQ 28.49
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.